3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
2
Conditions
Breast Neoplasms
14
Prostatic Neoplasms
4
Neoplasms
3
Carcinoma, Intraductal, Noninfiltrating
3
Precancerous Conditions
2
Peripheral Nervous System Diseases
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Cardiovascular Diseases
2
Breast Carcinoma In Situ
2
Weight Loss
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Psoriasis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polyps
1
Polycystic Ovary Syndrome
1
Pain
1
Ovarian Neoplasms
1
Osteoarthritis
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Monoclonal Gammopathy of Undetermined Significance
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Interventions
Oxaliplatin
112
Fluorouracil
104
Leucovorin
91
Irinotecan
91
Capecitabine
59
Bevacizumab
58
Cetuximab
46
Folfox protocol
28
Colonoscopy
24
Panitumumab
19
Chemotherapy, Adjuvant
19
Blood Specimen Collection
19
Drug Therapy
18
Nivolumab
17
Magnetic Resonance Spectroscopy
17
Radiotherapy
16
Exercise
16
Early Intervention, Educational
16
Surveys and Questionnaires
15
Laparoscopy
15
Surgical Procedures, Operative
13
Floxuridine
13
Biopsy
13
trifluridine tipiracil drug combination
12
pembrolizumab
12
XELOX
12
Neoadjuvant Therapy
11
Methods
11
Immunohistochemistry
11
Celecoxib
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Colonic Neoplasms
×
Fatty Acids, Omega-3
×
Clear all
NCT03661047
2021-11-17
OMICC
Massachusetts General Hospital
Phase 2
Withdrawn
NCT02231203
2018-07-31
EMPIRE
Medical Center Alkmaar
Phase 4
Completed
44 enrolled